C
CJ Bioscience Inc
KOSDAQ:311690
CJ Bioscience Inc
KOSDAQ:311690
Price:
9 060
KRW
-0.88%
Market Closed
Market Cap:
₩118.4B
Balance Sheet
Balance Sheet Decomposition
CJ Bioscience Inc
CJ Bioscience Inc
Balance Sheet Decomposition is not available for
CJ Bioscience Inc
CJ Bioscience Inc
Balance Sheet
CJ Bioscience Inc
CJ Bioscience Inc
Currency: KRW
| Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Cash & Cash Equivalents |
12 901
|
10 748
|
5 334
|
13 255
|
62 060
|
49 308
|
64 095
|
8 309
|
|
| Cash |
0
|
0
|
0
|
0
|
0
|
0
|
64 095
|
8 309
|
|
| Cash Equivalents |
12 901
|
10 748
|
5 334
|
13 255
|
62 060
|
49 308
|
0
|
0
|
|
| Short-Term Investments |
20
|
20
|
25 712
|
26 000
|
18 000
|
0
|
0
|
67 000
|
|
| Total Receivables |
305
|
405
|
214
|
409
|
721
|
1 025
|
540
|
967
|
|
| Accounts Receivables |
258
|
301
|
183
|
175
|
337
|
416
|
303
|
334
|
|
| Other Receivables |
47
|
104
|
31
|
234
|
383
|
609
|
236
|
632
|
|
| Inventory |
112
|
146
|
99
|
364
|
146
|
76
|
158
|
129
|
|
| Other Current Assets |
21
|
149
|
283
|
1 060
|
628
|
522
|
418
|
357
|
|
| Total Current Assets |
13 358
|
11 467
|
31 642
|
41 089
|
81 555
|
50 932
|
65 210
|
76 762
|
|
| PP&E Net |
1 247
|
921
|
1 728
|
19 991
|
9 856
|
14 364
|
12 707
|
8 907
|
|
| PP&E Gross |
1 247
|
921
|
1 728
|
19 991
|
9 856
|
14 364
|
12 707
|
8 907
|
|
| Accumulated Depreciation |
1 768
|
2 222
|
2 949
|
2 929
|
4 390
|
8 971
|
13 143
|
17 314
|
|
| Intangible Assets |
107
|
126
|
126
|
104
|
114
|
1 016
|
12 397
|
12 499
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
27
|
|
| Long-Term Investments |
0
|
0
|
0
|
7 744
|
24 082
|
23 957
|
0
|
0
|
|
| Other Long-Term Assets |
277
|
321
|
245
|
4 434
|
747
|
1 121
|
813
|
1 415
|
|
| Total Assets |
14 988
N/A
|
12 834
-14%
|
33 741
+163%
|
73 362
+117%
|
116 355
+59%
|
91 389
-21%
|
91 128
0%
|
99 610
+9%
|
|
| Liabilities | |||||||||
| Accounts Payable |
200
|
267
|
289
|
709
|
288
|
337
|
123
|
221
|
|
| Accrued Liabilities |
86
|
115
|
138
|
170
|
141
|
3 996
|
3 966
|
3 234
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
2 636
|
3 971
|
6 365
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
370
|
206
|
19 802
|
22 499
|
1 869
|
1 824
|
|
| Other Current Liabilities |
1 329
|
1 500
|
1 508
|
1 919
|
3 606
|
5 511
|
4 793
|
6 882
|
|
| Total Current Liabilities |
1 615
|
1 882
|
2 305
|
3 004
|
23 836
|
34 979
|
14 722
|
18 525
|
|
| Long-Term Debt |
0
|
0
|
368
|
35 560
|
4 088
|
3 831
|
2 692
|
1 162
|
|
| Other Liabilities |
210
|
175
|
214
|
314
|
577
|
2 924
|
2 218
|
2 166
|
|
| Total Liabilities |
1 825
N/A
|
2 057
+13%
|
2 887
+40%
|
38 878
+1 247%
|
28 502
-27%
|
41 734
+46%
|
19 633
-53%
|
21 853
+11%
|
|
| Equity | |||||||||
| Common Stock |
1 605
|
1 610
|
1 904
|
1 946
|
2 937
|
2 939
|
4 556
|
6 533
|
|
| Retained Earnings |
4 950
|
3 135
|
4 222
|
8 763
|
28 035
|
62 738
|
85 951
|
119 067
|
|
| Additional Paid In Capital |
16 522
|
12 299
|
33 160
|
41 247
|
109 877
|
105 757
|
149 117
|
187 110
|
|
| Unrealized Security Profit/Loss |
0
|
0
|
0
|
0
|
2 309
|
2 309
|
2 309
|
2 309
|
|
| Other Equity |
15
|
4
|
13
|
54
|
765
|
1 389
|
1 465
|
872
|
|
| Total Equity |
13 163
N/A
|
10 777
-18%
|
30 855
+186%
|
34 484
+12%
|
87 853
+155%
|
49 655
-43%
|
71 496
+44%
|
77 757
+9%
|
|
| Total Liabilities & Equity |
14 988
N/A
|
12 834
-14%
|
33 741
+163%
|
73 362
+117%
|
116 355
+59%
|
91 389
-21%
|
91 128
0%
|
99 610
+9%
|
|
| Shares Outstanding | |||||||||
| Common Shares Outstanding |
3
|
3
|
4
|
4
|
7
|
7
|
9
|
13
|
|
Switch to:
Switch to:
See Also
Discover More
